| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Loss on investment in equity securities | NaN | -96,965 | NaN | -95,794 |
| Net loss | -1,689,937 | -3,016,463 | -2,083,473 | -3,277,023 |
| Depreciation | 5,783 | 5,791 | 5,821 | 13,718 |
| Stock-based compensation | 787,374 | 1,386,213 | 1,136,217 | 1,620,386 |
| Inventory write-down | NaN | 11,460 | NaN | NaN |
| Other non-cash expenses, net | NaN | 7,843 | 25,963 | 317,279 |
| Loss on investment in equity securities | -31,416 | -652,979 | -150,029 | NaN |
| Short-term investments | -1,168 | NaN | NaN | NaN |
| Amortization of right-of-use asset | 86,373 | 208,252 | 90,190 | 181,062 |
| Inventory | NaN | 0 | 0 | 11,460 |
| Prepaid expenses and other current assets | -96,599 | -4,414 | 2,281 | 73,786 |
| Due from related parties | 133,778 | -68,798 | 14,905 | 190,394 |
| Accrued expenses and other current liabilities | -7,265 | 162,591 | -33,632 | 23,248 |
| Contract liabilities | NaN | -68,515 | NaN | NaN |
| Tax payable | -5,944 | 5,794 | -17,351 | 23,521 |
| Proceeds from related party payables | NaN | 0 | NaN | NaN |
| Tenant security deposit | 9,077 | -12,000 | -29,575 | 24,710 |
| Proceeds from issuance of warrants | NaN | 0 | NaN | 0 |
| Provision for doubtful accounts | NaN | 0 | NaN | NaN |
| Operating lease liabilities | -75,109 | -197,498 | -95,919 | -181,062 |
| Proceeds from private placement | NaN | 528,183 | 908,370 | 1,868,750 |
| Net cash used in operating activities | -894,243 | -587,582 | -964,710 | -1,434,007 |
| Proceeds from convertible notes payable third parties | NaN | 490,000 | 0 | 9,010 |
| Prepayment from related parties | NaN | NaN | 3,176 | 142,461 |
| Repayment of convertible notes payable third parties | NaN | 0 | 277,284 | NaN |
| Loan to related parties | NaN | 86,670 | 511,112 | 808,240 |
| Proceeds from convertible notes payable related parties | NaN | 390,000 | NaN | NaN |
| Payment for convertible notes receivable | 32,000 | NaN | NaN | NaN |
| Repayment from related parties | NaN | 203,026 | NaN | NaN |
| Repayment from related parties | -759,123 | 150,000 | NaN | NaN |
| Transaction costs for acquiring land | NaN | 373 | 5,421 | NaN |
| Prepayment for long-term investment | 680,000 | NaN | NaN | NaN |
| Proceeds from convertible notes payable - related party | NaN | NaN | 150,000 | NaN |
| Net cash provided by investing activities | 47,123 | -29,654 | -513,357 | -665,779 |
| Repurchase of treasury stocks | NaN | 0 | NaN | NaN |
| Repayment of short-term loans | 661,650 | 30,119 | 31,406 | 58,875 |
| Proceeds from issuance of a promissory note | NaN | 0 | NaN | 0 |
| Proceeds from exercise of warrants | 102,000 | 0 | 579,699 | 411,667 |
| Common stock subscription | 319,492 | -170,000 | NaN | 170,000 |
| Proceeds from short-term bank loans | NaN | NaN | NaN | 0 |
| Due to related parties, net | -57,554 | NaN | NaN | -44,469 |
| Net cash (used in) provided by financing activities | -342,181 | 1,078,064 | 1,203,848 | 2,356,083 |
| Effect of exchange rate changes on cash and cash equivalents and restricted cash | 2,640 | 12,246 | 51,804 | -43,786 |
| Net decrease in cash and cash equivalents and restricted cash | -1,186,661 | 473,074 | -222,415 | 212,511 |
| Beginning | 1,326,985 | 9,904 | 863,815 | NaN |
| Ending | 140,324 | 473,074 | 853,911 | NaN |
ABVC BIOPHARMA, INC. (ABVC)
ABVC BIOPHARMA, INC. (ABVC)